In 2022, the DSM-5-TR added “prolonged grief disorder” — a diagnosis that can be applied if intense longing for a deceased loved one persists past 12 months in adults. Defenders argue it captures a real subset of people who get stuck. Critics, including many bereavement researchers, argue it pathologizes a process that has always taken longer than a year and rebrands ordinary heartbreak as a billable mental illness. Both can be partly true. But the broader trend — treating grief as a disorder requiring clinical correction — has moved faster than the evidence justifies.
Grief was never supposed to be tidy
Most cultures, across most of history, have understood mourning as something that takes years and reshapes a person rather than something that resolves. The “five stages” model was originally about dying, not the bereaved, and even Elisabeth Kübler-Ross said it wasn’t a linear checklist. Modern grief research from George Bonanno and others suggests that resilience — not prolonged dysfunction — is the most common trajectory, and that most people integrate loss without clinical intervention. Calling grief that lasts longer than a calendar year a disorder imposes an arbitrary timeline on a deeply individual process.
Where the medical frame helps
None of this means therapy is useless or that severe grief never warrants professional care. A meaningful minority of bereaved people do develop complicated grief that genuinely impairs functioning — they can’t return to work, can’t care for surviving children, can’t get out of bed for years. For that group, structured grief therapy and, sometimes, medication can be life-changing. The argument isn’t that grief never needs help. It’s that the threshold for “needs treatment” has slid down to encompass experiences that used to be called Tuesday.
Pharma, billing codes, and the diagnosis incentive
A diagnosis unlocks insurance reimbursement, which means therapists, hospitals, and pharmaceutical companies all benefit when more human experiences get DSM codes. SSRIs are routinely prescribed for grief despite limited evidence they help uncomplicated bereavement and some evidence they may blunt the emotional processing the brain needs to do. The institutional incentive is to expand what counts as a disorder. The patient’s incentive is to know which version of suffering actually responds to which intervention.
What people grieving usually need
Time, ritual, community, and permission to not be okay are still the primary ingredients of recovery, and they don’t fit on a prescription pad. Talking to others who’ve lost someone, having work and relationships that allow grief to take up space, and not being told to be over it by month six does more than most clinical pathways. If grief is interfering with basic functioning long after a loss, professional support is worth seeking — but the goal should be integration, not elimination.
The bottom line
Some grief is clinical, but most grief is just grief, and treating ordinary mourning as a disorder hands a profoundly human experience to a system that’s rarely the right fit. The right question isn’t how fast the pain ends. It’s whether the person is slowly building a life around the loss.
Leave a Reply